

## Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer

Ernest K. Amankwah<sup>1</sup>, Linda E. Kelemen<sup>1</sup>, Qinggang Wang<sup>1</sup>, Honglin Song<sup>2</sup>, Georgia Chenevix-Trench<sup>5</sup>, on behalf of the Australian Ovarian Cancer Study Group; Jonathan Beesley<sup>5</sup>, Penelope M. Webb<sup>5</sup>, on behalf of the Australian Cancer Study (Ovarian Cancer); Celeste L. Pearce<sup>6</sup>, Anna H. Wu<sup>6</sup>, Malcolm C. Pike<sup>6,9</sup>, Daniel O. Stram<sup>6</sup>, Jenny Chang-Claude<sup>19</sup>, Shan Wang-Gohrke<sup>20</sup>, Roberta B. Ness<sup>10</sup>, Ellen L. Goode<sup>11</sup>, Julie M. Cunningham<sup>12</sup>, Brooke L. Fridley<sup>11</sup>, Robert A. Vierkant<sup>11</sup>, Shelley S. Tworoger<sup>13</sup>, Alice S. Whittemore<sup>7</sup>, Valerie McGuire<sup>7</sup>, Weiva Sieh<sup>7</sup>, Simon A. Gayther<sup>6</sup>, Aleksandra Gentry-Maharaj<sup>4</sup>, Usha Menon<sup>4</sup>, Susan J. Ramus<sup>6</sup>, Mary Anne Rossing<sup>15</sup>, Jennifer A. Doherty<sup>15</sup>, Marc T. Goodman<sup>16</sup>, Michael E. Carney<sup>16</sup>, Galina Lurie<sup>16</sup>, Lynne R. Wilkens<sup>16</sup>, Susanne Krüger Kjær<sup>21,22</sup>, Estrid Høgdal<sup>21</sup>, Daniel W. Cramer<sup>14</sup>, Kathryn L. Terry<sup>14</sup>, Montserrat Garcia-Closas<sup>3,17</sup>, Hannah Yang<sup>17</sup>, Jolanta Lissowska<sup>23</sup>, Hoda Anton-Culver<sup>8</sup>, Argyrios Ziogas<sup>8</sup>, Joellen M. Schildkraut<sup>18</sup>, Andrew Berchuck<sup>18</sup>, Paul D.P. Pharoah<sup>2</sup>, on behalf of the Ovarian Cancer Association Consortium.

### Abstract

**Background:** We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI = 1.0–1.4,  $P_{\text{trend}} = 0.01$ ) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1–1.5,  $P_{\text{trend}} = 0.003$ ).

**Methods:** We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium.

**Results:** No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9–1.1,  $P_{\text{trend}} = 0.61$ ; serous: OR = 1.0, 95% CI = 0.9–1.1,  $P_{\text{trend}} = 0.85$ ) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0–1.1,  $P_{\text{trend}} = 0.28$ ; serous: OR = 1.1, 95% CI = 1.0–1.2,  $P_{\text{trend}} = 0.11$ ). There was no evidence for statistical heterogeneity in ORs across the studies.

**Conclusions:** Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study.

**Impact:** Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations. *Cancer Epidemiol Biomarkers Prev*; 20(5); 1028–31. ©2011 AACR.

### Introduction

Invasive epithelial ovarian cancer (EOC) has a recognized genetic component, but known high penetrance

genes, such as *BRCA1* and *BRCA2*, explain less than 10% of EOC risk (1). The remaining unexplained risk is probably caused by a combination of multiple low to moderate penetrance genetic variants (2).

**Authors' Affiliation:** <sup>1</sup>Department of Population Health Research, Alberta Health Services-Cancer Care, Calgary, Canada; <sup>2</sup>Cancer Research United Kingdom Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge; <sup>3</sup>Institute of Cancer Research, Sections of Epidemiology and Cancer Genetics and The Breakthrough Breast Cancer Research Centre; <sup>4</sup>Department of Gynaecological Oncology, University College London EGA Institute for Women's Health, London, United Kingdom; <sup>5</sup>Queensland Institute of Medical Research, Brisbane, Australia; <sup>6</sup>University of Southern California, Keck School of Medicine, Los Angeles; <sup>7</sup>Stanford University School of Medicine, Stanford; <sup>8</sup>Department of Epidemiology, School of Medicine, University of California, Irvine, California; <sup>9</sup>Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York; <sup>10</sup>University of Texas School of Public Health, Houston, Texas; <sup>11</sup>Department of Health Sciences Research; <sup>12</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; <sup>13</sup>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Department of Epidemiology, Harvard School of Public Health; <sup>14</sup>Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, and Department of Epidemiol-

ogy, Harvard School of Public Health, Boston, Massachusetts; <sup>15</sup>Fred Hutchinson Cancer Research Center, Seattle, Washington; <sup>16</sup>Cancer Research Center, University of Hawaii, Honolulu, Hawaii; <sup>17</sup>Division of Cancer Genetics and Epidemiology, National Cancer Institute, NIH, Rockville, Maryland; <sup>18</sup>Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina; <sup>19</sup>Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; <sup>20</sup>Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany; <sup>21</sup>Danish Cancer Society; <sup>22</sup>Gynecologic Clinic, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; and <sup>23</sup>Department of Cancer Epidemiology and Prevention, The M. Skłodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland

**Corresponding Author:** Linda E. Kelemen, Department of Population Health Research, Alberta Health Services-Cancer Care, Calgary, Canada; Phone: 403-521-3726; Fax: 403-270-8003. E-mail: LKelemen@post.harvard.edu

doi: 10.1158/1055-9965.EPI-11-0053

©2011 American Association for Cancer Research.

**Table 1.** Genotype counts and statistics for rs2660753 among white non-Hispanic ovarian cancer cases (all histologies) and controls in OCAC studies.

Study <sup>a</sup>	Controls <sup>b</sup>			Cases <sup>b</sup>			MAF <sup>b</sup>	P <sub>HWE</sub> <sup>b</sup>	OR (95% CI) <sup>c</sup>	P <sub>trend</sub>
	AA	Aa	aa	AA	Aa	aa				
Discovery set										
STA	141	39	1	197	67	3	0.11	0.48	1.3 (0.8–2.0)	0.24
UKO	467	89	5	366	95	5	0.09	0.79	1.3 (1.0–1.8)	0.10
MAL	677	115	2	368	66	4	0.07	0.30	1.2 (0.8–1.6)	0.37
SEA	1020	187	6	645	142	10	0.08	0.57	1.3 (1.0–1.6)	0.03
Summary, discovery	2,305	430	14	1,576	370	22	0.08	0.26	1.2 (1.1–1.4)	0.004
Replication set										
HAW	123	33	2	53	16	0	0.12	1.0	0.9 (0.5–1.7)	0.71
NHS	271	80	6	84	21	3	0.13	0.97	1.0 (0.6–1.5)	0.90
MAY	306	58	5	221	54	0	0.09	0.22	1.1 (0.7–1.6)	0.68
GER	341	83	6	174	31	1	0.11	0.63	0.7 (0.5–1.1)	0.09
UCI	350	93	8	225	44	7	0.12	0.51	0.9 (0.6–1.2)	0.46
USC	376	108	11	297	73	5	0.13	0.32	0.8 (0.6–1.1)	0.24
POL	435	142	18	187	68	2	0.15	0.14	0.9 (0.7–1.2)	0.60
HOP	453	131	10	227	57	7	0.13	0.85	0.9 (0.7–1.3)	0.69
DOV	572	141	6	419	105	7	0.11	0.56	1.1 (0.8–1.4)	0.66
NCO	575	153	9	491	112	2	0.12	0.86	0.8 (0.6–1.0)	0.09
NEC	692	179	18	450	150	13	0.12	0.11	1.2 (1.0–1.5)	0.12
AUS	884	202	14	685	182	9	0.11	0.52	1.1 (0.9–1.4)	0.34
Summary, replication	5,378	1,403	113	3,513	913	56	0.12	0.06	1.0 (0.9–1.1)	0.61
Summary, combined	7,683	1,833	127	5,089	1,283	78	0.11	0.14	1.0 (1.0–1.1)	0.28

<sup>a</sup>STA, GEOCS (Genetic Epidemiology of Ovarian Cancer Study), California; UKO, UKOPS (United Kingdom Ovarian Cancer Population Study), United Kingdom; MAL, MALOVA (Malignant Ovarian Cancer Study), Denmark; SEA, SEARCH (Studies of Epidemiology and Risk Factors in Cancer Heredity Ovarian Cancer Study), England; HAW, HAWAII (Hawaii Ovarian Cancer Study), Hawaii; NHS (Nurses' Health Study); MAY, MAYO (Mayo Clinic Ovarian Cancer Case Control Study), Mid-west; GER, GOCS (German Ovarian Cancer Study), Germany; UCI (the Orange and San Diego Counties California Study), California; USC, LAC-CCOC (Los Angeles County Case-Control Studies of Ovarian Cancer), California; POL (Polish Ovarian Cancer Study), Poland; HOP, HOPE (Hormones and Ovarian Cancer Prediction Study), Pittsburg; DOV, DOVE (Diseases of the Ovary and their Evaluation), Washington; NCO, NCOCS (North Carolina Ovarian Cancer Study), North Carolina; NEC, NECC (New England based Case-Control Study), New England; AUS, AOCS (Australian Ovarian Cancer Study) and ACS (Australian Cancer Study-Ovarian cancer), Australia.

<sup>b</sup>AA, homozygous major allele; Aa, heterozygous; aa, homozygous minor allele; MAF, minor allele frequency in controls; P<sub>HWE</sub>, P values from the chi-square test assessing deviation of genotype frequencies among controls from those expected under HWE.

<sup>c</sup>OR and 95% CI adjusted for age (<40, 40–49, 50–59, 60–69, and ≥70 years) in study-specific analyses and for age and study in summary analyses.

We previously reported an association between rs2660753 on chromosome 3p12 and invasive EOC (OR = 1.2, 95% CI = 1.0–1.4, P<sub>trend</sub> = 0.01, 1,973 cases/3,419 controls) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1–1.5, P<sub>trend</sub> = 0.003, 901 cases/3,303 controls; ref. 3). rs2660753 is a prostate cancer susceptibility polymorphism identified from a genome-wide association study of Europeans (4) and replicated in independent populations of European (5) and non-European (6) ancestry. The nearest genes (70–198 kb away) to rs2660753, *VGLL3*, *CHMP2B*, and *Pit-1/POU1F1*, encode proteins with potential roles in tumorigenesis (3) and the 3p12.3-pcen

region has been identified as a candidate tumor suppressor gene locus (7).

In this investigation, we sought to replicate the association between rs2660753 and invasive EOC in a larger sample of 12 additional studies from the international Ovarian Cancer Association Consortium (OCAC) comprising 4,482 cases and 6,894 controls.

## Materials and Methods

### Study population

Sixteen ovarian cancer case-control studies contributed data to this analysis. Four of the studies were included in

our initial report (discovery set; ref. 3) and 12 were included in follow up genotyping (replication set). Details of each of the studies have been published previously (8). Each study received ethics committee approval and all study subjects provided informed written consent. Pathologic and questionnaire data included tumor behavior, histology, age at diagnosis (or comparable date for controls), family history of breast or ovarian cancer and ethnicity/race.

### Genotyping

Genotyping was carried out by using the 5' nuclease Taqman allelic discrimination assay (Applied Biosystems), except the Australian Ovarian Cancer Study and the Australian Cancer Study-Ovarian Cancer that used the Sequenom iPLEX protocol (Sequenom Inc.), and by using similar conditions as the original study (3). Consistency across laboratories was assessed by genotyping a common set of 95 DNAs (90 CEPH trios and 5 duplicate samples) with 98% or more concordance in genotype calls. Details of OCAC's criteria for acceptable genotyping have been described previously (8).


### Statistical analysis

Analyses were restricted to white non-Hispanic subjects. We excluded cases with non-EOC and borderline tumors. Genotypes of participants were used to estimate allele frequencies and departure from Hardy-Weinberg equilibrium (HWE) was assessed in controls by using

a chi-squared test. Single nucleotide polymorphism associations were evaluated by using unconditional logistic regression under ordinal and codominant genetic models to estimate ORs and 95% CIs. Statistical models were adjusted for age (<40, 40–49, 50–59, 60–69, and  $\geq$ 70 years) in study-specific analyses and for age and study in combined analyses. Prior to pooling, tests of heterogeneity in ORs across studies were conducted by using the likelihood ratio test comparing models with and without a product term for genotype and study. Statistical tests were implemented with SAS software (SAS Institute).

### Results

Genotype distributions for controls in all the studies were consistent with HWE (Table 1). No evidence for an association was observed at rs2667053 in the replication set (OR = 1.0, 95% CI = 0.9–1.1,  $P_{\text{trend}} = 0.61$  for all 4,482 cancers and OR = 1.0, 95% CI = 0.9–1.1,  $P_{\text{trend}} = 0.85$  for 2,515 serous cancers) or in the combined discovery and replication sets (OR = 1.0, 95% CI = 1.0–1.1,  $P_{\text{trend}} = 0.28$  for all 6,450 cancers and OR = 1.1, 95% CI = 1.0–1.2,  $P_{\text{trend}} = 0.11$  for 3,563 serous cancers) under the ordinal model (Fig. 1). No statistically significant associations were observed under the codominant model (data not shown). There was no statistical heterogeneity in ORs for all ovarian cancers or serous cancers when the discovery and replication sets were combined ( $P_{\text{heterogeneity}} > 0.10$ ).



**Figure 1.** Funnel plot of study-specific and summary OR and 95% CI for the association between rs2667053 and serous ovarian cancer among white non-Hispanic subjects in OCAC studies by using the ordinal genetic risk model. Squares (■) indicate study-specific OR; the size of squares is proportional to study-specific sample size; the width of lines (–) indicate the study-specific 95% CI; diamonds (◆) indicate summary OR; and the width of diamonds indicate summary 95% CI. Refer to footnote of Table 1 for study nomenclature.

Analyses stratified by family history of breast or ovarian cancer in first-degree relatives did not show statistically significant associations for all cancers (OR = 0.9,  $P = 0.67$ , 481 cases with family history and OR = 1.0,  $P = 0.81$ , 1,576 cases without family history) or for serous cancers (OR = 1.1,  $P = 0.70$ , 297 cases with family history and OR = 1.0,  $P = 0.93$ , 928 cases without family history).

## Discussion

Our findings, based on 12 studies participating in the international OCAC, do not support an association between rs2667053 and invasive EOC overall or for the serous histological type. We used a larger sample size and applied similar assays and stringent quality control criteria to genotype data as in the original study. In the current study, the power to detect an OR of 1.2, as previously reported (3), with minor allele frequency of 0.12 and Type 1 error of 0.01 was 87%. To detect smaller effects, as observed for serous cancers in the current study, a much larger sample is required. There was no evidence of statistical heterogeneity in ORs across studies or of effect modification by family history. Although variant rs2667053 is a strong candidate for prostate cancer susceptibility, it does not seem to be a candidate risk factor for ovarian cancer.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

The Australian Ovarian Cancer Study (AOCS) Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, and P.M. Webb) gratefully acknowledges the contribution of all the clinical and scientific collaborators (see <http://www.aocstudy.org/>). The Australian Cancer Study Management Group (A. Green, P. Parsons, N. Hayward, P. M. Webb, and D. Whiteman) thank all of the project staff, collaborating institutions, and study participants. The German Ovarian Cancer Study

(GER) acknowledges Ursula Eilber and Tanja Koehler for technical assistance with the study. The Polish Ovarian Cancer Study (POL) thanks Drs Louise Brinton, Mark Sherman, Stephen Chanock of the National Cancer Institute, Prof Neolina Szeszenia-Dabrowska and Dr Beata Peplonska of the Nofer Institute of Occupational Medicine (Lodz, Poland), Prof Witold Zatonski of the M Skłodowska-Curie Cancer Center and Institute of Oncology (Warsaw, Poland), and Pei Chao and Jane Wang (IMS, Silver Spring, MD) for their contribution. The United Kingdom Ovarian Cancer Population Study (UKO) is thankful to all members of the research team, including nurses, scientists, data entry personnel, and consultant gynaecological oncologists.

## Grant Support

The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith. Funding for the individual participating studies was provided by: the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council Tasmania and Cancer Foundation of Western Australia (AOCS study), and the National Health and Medical Research Council of Australia (199600; ACS study); G. C.-Trench and P. M. Webb are supported by the NHMRC of Australia; U.S. NIH grants R01-CA-112523 and R01-CA-87538 (DOV); the German Federal Ministry of Education and Research, the Program of Clinical Biomedical Research 01 GB 9401, the state of Baden-Württemberg through the Medical Faculty, University of Ulm P.685 and the German Cancer Research Center (GER); the U.S. National Institutes of Health (R01 CA 58598, N01-CN-55424, N01-PC-67001; HAW); Mermaid 1, The Danish Cancer Society and the National Cancer Institute R01-CA-61107 (MAL); National Cancer Institute R01-CA-122443 and R01-CA-122443 (MAY); National Cancer Institute R01-CA-76016 (NCO); U.S. National Institutes of Health P01 CA87969 and R01 CA94949 (NHS); National Institutes of Health R01 CA54419 and P50 CA105009 (NEC); Intramural Funds from the U.S. National Cancer Institute, National Institutes of Health, Division of Cancer Epidemiology and Genetics (POL); U.S. National Institutes of Health U01 CA71966, R01 CA16056, and U01 CA69417 for recruitment of controls by the Northern California Cancer Center (STA); Cancer Research UK (SEA); National Cancer Institute CA-58860 and CA-92044 and the Lon V Smith Foundation LVS-39420 (UCI); Cancer Research UK, the Eve Appeal, the OAK Foundation and the Department of Health's NIHR Biomedical Research Centre funding scheme (UKO); the California Cancer Research Program grants 00-01389V-20170 and 2110200, U.S. Public Health Service grants CA14089, CA17054, CA61132, CA63464, N01-PC-67010 and R03-CA113148, and California Department of Health Services sub-contract 050-E8709 (USC). E. K. Amankwah is supported by a fellowship from the Alberta Heritage Foundation for Medical Research. L. E. Kelemen is supported by Alberta Cancer Research Institute and the Canadian Institutes of Health Research Investigator award.

Received January 17, 2011; accepted January 24, 2011; published OnlineFirst March 17, 2011.

## References

1. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. *Genet Epidemiol* 2000;18:173-90.
2. Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, et al. Role of genetic polymorphisms and ovarian cancer susceptibility. *Mol Oncol* 2009;3:171-81.
3. Song H, Koessler T, Ahmed S, Ramus SJ, Kjaer SK, Dicioccio RA, et al. Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. *Cancer Res* 2008;68:8837-42.
4. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. *Nat Genet* 2008;40:316-21.
5. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. *Cancer Epidemiol Biomarkers Prev* 2008;17:2052-61.
6. Waters KM, Le Marchand L, Kolonel LN, Monroe KR, Stram DO, Henderson BE, et al. Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. *Cancer Epidemiol Biomarkers Prev* 2009;18:1285-9.
7. Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, et al. Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. *Mol Carcinog* 2009;48:1077-92.
8. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. *Int J Cancer* 2008;123:380-8.